DERM is the world first and only autonomously AI for skin cancer dermoscopy that is regulatory approved as a class III medical device to direct patient management. DERM can automatically rule out benign exams and refer patients based solely on AI analysis of dermoscopy images.
Skin Analytics’ Class III CE marked AI as a Medical Device (AIaMD), DERM (Deep Ensemble for the Recognition of Malignancy), is built around our custom built teledermatology platform to help triage patients into the right place, at the right time and to conserve dermatologist capacity for patients who need it.
DERM is regulatory approved to direct patient management autonomously within skin cancer dermatoscopy. DERM can be operated by a trained non-clinical person and can stand alone rule out 50% of all exams for skin cancer, for immediately discharge and refer patients based on AI analysis of dermoscopy images.
Implemented at scale DERM can:
Since 2020, Skin Analytics has assessed over 250,000 NHS patients for suspicion of skin cancer, helping Secondary Care organisations remove the need for up to 95% of face-to-face NHS urgent suspected skin cancer appointments.
DERM is in live clinical use across more than 30 NHS trusts and is used autonomously both in primary care GP settings and in secondary care hospital settings.
Clinical performance over time
Skin Analytics have pioneered a market leading approach to performance monitoring for their AI as a medical device, DERM.
They are committed to providing the best technology and being completely transparent about their results.
This table is a summary of performance since December 2023 up to Q1 2025 Post Market Surveillance Reports, with analysis based on lesion outcomes
How do Skin Analytics set performance targets?
Performance targets are based on clinical performance published in the literature and agreed by their Clinical Advisory Committee which is composed of leading UK and international dermatologists and health economics experts.
Skin cancer 
+45 60 14 18 84
fba@humanbytes.ai